MTNB

Matinas BioPharma Holdings, Inc. (MTNB) | Rumor.io

Matinas BioPharma Holdings

MTNB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,551

Bullish sentiment (50-day avg)97%

Price to earnings ratio-1.27

Market capitalization2.5M

Earnings per share-1.15

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.3M

Social

What share of all stock conversation is about MTNB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0.01% +0.01	0% +0	0% 0

Sep 29

Matinas BioPharma Holdings, Inc. ($MTNB) is set to announce a merger, which could lead to a significant increase in stock value.
The merger agreement values Matinas as a company at $25M, and the current market cap is $2.9M, suggesting a potential undervaluation.
If the merger closes, the stock price could run similar to $AEMD, and some analysts are predicting a price of $5.00 or higher.

Generated by AI

Sentiment

Of the messages about MTNB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.77% +98.77	97.56% -2.44	98.62% +3.56	70.3% +17.14
Bearish	1.23% -98.77	2.44% new	1.38% -3.56	29.7% -17.14

Bullish· Jul 27

$MTNB is expected to fly in the early morning hours, with a potential 57% gain by open.
The stock is very bullish for Monday, with a target price of $1 and a 115% gain confirmed.
$MTNB is ripping 58% to $0.38 on massive volume, with potential for further gains if it can handle the $0.40 level.

Bearish· Jul 27

The company has ended its at-the-market sales agreement, potentially increasing supply and negatively impacting the stock price.
The CEO, Jerry Jabbour, has been criticized for his tenure, with some calling him the worst in the history of clinical stage biotech companies.
The stock's price has been impacted by the issuance of new shares, with millions potentially becoming available to sell, increasing supply and putting downward pressure on the price.

Generated by AI

Topics

Of the messages about MTNB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	78.72%	78.72%	88.04%	62.96%
Technical Analysis	0%	0%	0%	33.89%
Analysts	0%	0%	0%	0.56%
Macro	0%	0%	1.09%	0.19%
Controversies	21.28%	21.28%	10.87%	2.41%
Earnings	0%	0%	0%	0%

Announcements· Jul 13

Matinas BioPharma Holdings, Inc. ($MTNB) is merging with GH Power, a clean energy and critical materials company, to create a publicly traded clean energy and green hydrogen company.
Under the terms of the deal, Matinas shareholders will retain approximately 9% equity in the combined entity, while GH Power holders will own around 91%.
The company is also selling its LNC platform technology and lead product candidate MAT2203 to Azurity Pharmaceuticals for $4 million upfront.

Technical Analysis· Oct 11

Resistance levels for $MTNB include $0.2804 and $0.2652, with a potential breakout above $0.39.
A cup and handle breakout is visible on the chart, with a potential target of $0.825 if the breakout above $0.702 is confirmed.
Key levels for $MTNB include $0.35, $0.355, and $0.40, with the potential for a significant move if the stock breaks above or below these levels.

Generated by AI

Community

Of the messages about MTNB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	6.67%	4.56%	4.78%	11.73%
Newcomers	93.33%	95.44%	95.22%	88.27%

Regulars· Jul 27

$MTNB is showing strength with no signs of weakness, according to regulars.
The asset's price is moving upward, with some considering it for a top list.
There is a shortage of short shares available due to high demand, which may impact trading.

Newcomers· Aug 19

Matinas BioPharma has received a Notice of Allowance for a US patent titled "ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS", which could be a significant development for the company.
Newcomers are speculating about the potential impact of the patent news on the stock price, with some wondering if it will lead to a increase in the stock's value.
The patent news has led to a significant decline in the stock price, with some users expressing surprise and disappointment, while others are holding onto their shares, hoping for a rebound.

Generated by AI

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.

26d agoYahoo Finance

12 Health Care Stocks Moving In Monday's Pre-Market Session - Matinas BioPharma Hldgs (AMEX:MTNB), Forte

Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose

2mo agoBenzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - NextCure (NASDAQ:NXTC), Shuttle Pharmaceut

Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved

2mo agoBenzinga

GH Power to go public via merger with Matinas BioPharma

2mo agoInvesting.com

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization Business Combination expected to provide public market platform to accelerate commercialization, project development and strategic growth across North America and Europe Definitive agreement provides for the sale of Matinas BioPharma Nanotechnologies, Inc., including MAT2203 and the LNC technology platform, to Azurity Pharmaceuticals f

2mo agoYahoo Finance

Also Discussed

Investors talking about MTNB also mention

#	Name	Attention
1	Amarin Corporation plc ADRAMRN	0%+0
2	Corbus Pharmaceuticals Holdings, Inc.CRBP	0%0
3	Mangoceuticals, Inc.MGRX	0%0
4	Tempest Therapeutics Inc.TPST	0%+0
5	Oragenics Inc.OGEN	0%0
6	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
7	Motus GI Holdings Inc.MOTS	0%new
8	NGM - NGM Biopharmaceuticals, Inc.	——
9	Keros Therapeutics, Inc.KROS	0%new
10	RedHill Biopharma Ltd. American Depositary SharesRDHL	0%0

Matinas BioPharma Holdings, Inc.

Healthcare
Biotechnology

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its current work has centered on anti-infective applications, including MAT2203, an oral formulation of amphotericin B, alongside additional discovery programs in oncology and inflammation. Matinas BioPharma Holdings, Inc. operates from Bedminster, New Jersey and remains positioned as a developer of novel drug-delivery solutions within the healthcare and biotechnology market.

Website

Location

1545 Route 206 South

Bedminster, NJ, 07921

United States

Social

What share of all stock conversation is about MTNB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0.01% +0.01	0% +0	0% 0

Sep 29

Matinas BioPharma Holdings, Inc. ($MTNB) is set to announce a merger, which could lead to a significant increase in stock value.
The merger agreement values Matinas as a company at $25M, and the current market cap is $2.9M, suggesting a potential undervaluation.
If the merger closes, the stock price could run similar to $AEMD, and some analysts are predicting a price of $5.00 or higher.

Generated by AI

Sentiment

Of the messages about MTNB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	98.77% +98.77	97.56% -2.44	98.62% +3.56	70.3% +17.14
Bearish	1.23% -98.77	2.44% new	1.38% -3.56	29.7% -17.14

Bullish· Jul 27

$MTNB is expected to fly in the early morning hours, with a potential 57% gain by open.
The stock is very bullish for Monday, with a target price of $1 and a 115% gain confirmed.
$MTNB is ripping 58% to $0.38 on massive volume, with potential for further gains if it can handle the $0.40 level.

Bearish· Jul 27

The company has ended its at-the-market sales agreement, potentially increasing supply and negatively impacting the stock price.
The CEO, Jerry Jabbour, has been criticized for his tenure, with some calling him the worst in the history of clinical stage biotech companies.
The stock's price has been impacted by the issuance of new shares, with millions potentially becoming available to sell, increasing supply and putting downward pressure on the price.

Generated by AI

Topics

Of the messages about MTNB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	78.72%	78.72%	88.04%	62.96%
Technical Analysis	0%	0%	0%	33.89%
Analysts	0%	0%	0%	0.56%
Macro	0%	0%	1.09%	0.19%
Controversies	21.28%	21.28%	10.87%	2.41%
Earnings	0%	0%	0%	0%

Announcements· Jul 13

Matinas BioPharma Holdings, Inc. ($MTNB) is merging with GH Power, a clean energy and critical materials company, to create a publicly traded clean energy and green hydrogen company.
Under the terms of the deal, Matinas shareholders will retain approximately 9% equity in the combined entity, while GH Power holders will own around 91%.
The company is also selling its LNC platform technology and lead product candidate MAT2203 to Azurity Pharmaceuticals for $4 million upfront.

Technical Analysis· Oct 11

Resistance levels for $MTNB include $0.2804 and $0.2652, with a potential breakout above $0.39.
A cup and handle breakout is visible on the chart, with a potential target of $0.825 if the breakout above $0.702 is confirmed.
Key levels for $MTNB include $0.35, $0.355, and $0.40, with the potential for a significant move if the stock breaks above or below these levels.

Generated by AI

Community

Of the messages about MTNB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	6.67%	4.56%	4.78%	11.73%
Newcomers	93.33%	95.44%	95.22%	88.27%

Regulars· Jul 27

$MTNB is showing strength with no signs of weakness, according to regulars.
The asset's price is moving upward, with some considering it for a top list.
There is a shortage of short shares available due to high demand, which may impact trading.

Newcomers· Aug 19

Matinas BioPharma has received a Notice of Allowance for a US patent titled "ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS", which could be a significant development for the company.
Newcomers are speculating about the potential impact of the patent news on the stock price, with some wondering if it will lead to a increase in the stock's value.
The patent news has led to a significant decline in the stock price, with some users expressing surprise and disappointment, while others are holding onto their shares, hoping for a rebound.

Generated by AI

Matinas BioPharma Holdings

Social

Sep 29

Bullish· Jul 27

Bearish· Jul 27

Announcements· Jul 13

Technical Analysis· Oct 11

Regulars· Jul 27

Newcomers· Aug 19

Matinas BioPharma announces one-for-fifteen reverse stock split approval

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

12 Health Care Stocks Moving In Monday's Pre-Market Session - Matinas BioPharma Hldgs (AMEX:MTNB), Forte

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - NextCure (NASDAQ:NXTC), Shuttle Pharmaceut

GH Power to go public via merger with Matinas BioPharma

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Also Discussed

Matinas BioPharma Holdings, Inc.

Company Information

Location

Matinas BioPharma announces one-for-fifteen reverse stock split approval

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

12 Health Care Stocks Moving In Monday's Pre-Market Session - Matinas BioPharma Hldgs (AMEX:MTNB), Forte

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - NextCure (NASDAQ:NXTC), Shuttle Pharmaceut

GH Power to go public via merger with Matinas BioPharma

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Also Discussed

Social

Sep 29

Bullish· Jul 27

Bearish· Jul 27

Announcements· Jul 13

Technical Analysis· Oct 11

Regulars· Jul 27

Newcomers· Aug 19